Daily Stock Analysis, AEMD, Aethlon Medical Inc, priceseries

Aethlon Medical Inc. Daily Stock Analysis
Stock Information
Open
0.77
Close
0.80
High
0.85
Low
0.70
Previous Close
0.76
Daily Price Gain
0.05
YTD High
1.71
YTD High Date
Jan 2, 2019
YTD Low
0.63
YTD Low Date
Apr 18, 2019
YTD Price Change
-0.78
YTD Gain
-49.24%
52 Week High
1.74
52 Week High Date
Nov 27, 2018
52 Week Low
0.63
52 Week Low Date
Apr 18, 2019
52 Week Price Change
-0.51
52 Week Gain
-38.78%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 30. 2017
4.00
Feb 7. 2017
4.25
6 Trading Days
6.26%
Link
LONG
Mar 13. 2017
4.40
Mar 16. 2017
4.65
3 Trading Days
5.78%
Link
LONG
Jun 14. 2017
2.40
Jun 15. 2017
2.58
1 Trading Days
7.71%
Link
LONG
Dec 12. 2017
1.04
Dec 18. 2017
1.15
4 Trading Days
10.13%
Link
LONG
Dec 29. 2017
1.13
Jan 8. 2018
1.24
5 Trading Days
10.18%
Link
LONG
Sep 17. 2018
1.03
Oct 4. 2018
1.16
13 Trading Days
13.05%
Link
LONG
Dec 21. 2018
1.32
Jan 10. 2019
1.42
12 Trading Days
7.75%
Link
Company Information
Stock Symbol
AEMD
Exchange
NasdaqCM
Company URL
http://www.aethlonmedical.com
Company Phone
858-459-7800
CEO
James A. Joyce
Headquarters
California
Business Address
9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO, CA 92123
Sector
-
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0000882291
About

Aethlon Medical, Inc. is a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.

Description

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in cancer, infectious diseases, and other life-threatening conditions in the United States. The company develops Aethlon Hemopurifier, a medical device, which targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Its Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. The company is also involved in developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. Aethlon Medical, Inc. was founded in 1991 and is based in San Diego, California.